Cristin-resultat-ID: 2103635
Sist endret: 17. februar 2023, 14:54
NVI-rapporteringsår: 2022
Resultat
Vitenskapelig oversiktsartikkel/review
2022

Hepatitis E Virus (HEV) Synopsis: General Aspects and Focus on Bangladesh

Bidragsytere:
  • Asma Binte Aziz
  • Joakim Øverbø
  • Susanne Dudman
  • Cathinka Halle Julin
  • Yoon Jeong Gabby Kwon
  • Yasmin Jahan
  • mfl.

Tidsskrift

Viruses
ISSN 1999-4915
e-ISSN 1999-4915
NVI-nivå 1

Om resultatet

Vitenskapelig oversiktsartikkel/review
Publiseringsår: 2022
Trykket: 2023
Volum: 15:63
Hefte: 1
Sider: 1 - 15
Open Access

Importkilder

Scopus-ID: 2-s2.0-85147045936

Klassifisering

Vitenskapsdisipliner

Medisinsk immunologi

Beskrivelse Beskrivelse

Tittel

Hepatitis E Virus (HEV) Synopsis: General Aspects and Focus on Bangladesh

Sammendrag

HEV is the most common cause of acute hepatitis globally. This review summarizes the latest knowledge on the epidemiology, clinical characteristics, testing, and treatment of HEV infection. We also focused on Bangladesh to highlight the distinct challenges and the possible remedies. In low-income settings, the virus is mainly transmitted between people by fecal contamination of drinking water causing large outbreaks, and sporadic cases. The disease is usually mild and self-limiting acute hepatitis. Still, pregnant women and their offspring in low-income countries are at particular risk for severe disease, with up to 20% maternal mortality. Despite the high burden of the disease, HEV remains a relatively neglected virus, with detection hampered by costly tests and a lack of suitable treatments. Molecular PCR diagnostics, together with ELISA antibody tests, remain the preferred methods for diagnosis of HEV; however, rapid bedside diagnostics are available and could offer a practical alternative, especially in low-income countries. One vaccine (HEV 239) is only available in China and Pakistan, as efficacy against the other genotypes remains uncertain. The effectiveness trial conducted in Bangladesh might lead the way in gathering more efficacy data and could, together with improved surveillance and raised awareness, dramatically reduce the global burden of HEV.

Bidragsytere

Asma Binte Aziz

  • Tilknyttet:
    Forfatter
    ved Avdeling for mikrobiologi ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Sør-Korea

Joakim Øverbø

  • Tilknyttet:
    Forfatter
    ved Avdeling for smittevern og vaksine ved Folkehelseinstituttet
  • Tilknyttet:
    Forfatter
    ved Avdeling for mikrobiologi ved Universitetet i Oslo

Susanne Dudman

  • Tilknyttet:
    Forfatter
    ved Avdeling for mikrobiologi ved Universitetet i Oslo

Cathinka Halle Julin

  • Tilknyttet:
    Forfatter
    ved Helsetjenester ved Folkehelseinstituttet

Yoon Jeong Gabby Kwon

  • Tilknyttet:
    Forfatter
    ved Carnegie Mellon University
1 - 5 av 8 | Neste | Siste »